These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 22972611)

  • 41. Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer.
    Gabrielli B; Bokhari F; Ranall MV; Oo ZY; Stevenson AJ; Wang W; Murrell M; Shaikh M; Fallaha S; Clarke D; Kelly M; Sedelies K; Christensen M; McKee S; Leggatt G; Leo P; Skalamera D; Soyer HP; Gonda TJ; McMillan NA
    Mol Cancer Ther; 2015 Dec; 14(12):2753-61. PubMed ID: 26516156
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.
    Tentler JJ; Ionkina AA; Tan AC; Newton TP; Pitts TM; Glogowska MJ; Kabos P; Sartorius CA; Sullivan KD; Espinosa JM; Eckhardt SG; Diamond JR
    Mol Cancer Ther; 2015 May; 14(5):1117-29. PubMed ID: 25758253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.
    Niu H; Shin H; Gao F; Zhang J; Bahamon B; Danaee H; Melichar B; Schilder RJ; Coleman RL; Falchook G; Adenis A; Behbakht K; DeMichele A; Dees EC; Perez K; Matulonis U; Sawrycki P; Huebner D; Ecsedy J
    EBioMedicine; 2017 Nov; 25():50-57. PubMed ID: 29122619
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.
    Currier MA; Sprague L; Rizvi TA; Nartker B; Chen CY; Wang PY; Hutzen BJ; Franczek MR; Patel AV; Chaney KE; Streby KA; Ecsedy JA; Conner J; Ratner N; Cripe TP
    Oncotarget; 2017 Mar; 8(11):17412-17427. PubMed ID: 28147331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aurora kinases as targets in drug-resistant neuroblastoma cells.
    Michaelis M; Selt F; Rothweiler F; Löschmann N; Nüsse B; Dirks WG; Zehner R; Cinatl J
    PLoS One; 2014; 9(9):e108758. PubMed ID: 25268132
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas.
    Islam S; Qi W; Morales C; Cooke L; Spier C; Weterings E; Mahadevan D
    Mol Cancer Ther; 2017 Oct; 16(10):2083-2093. PubMed ID: 28615297
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
    Liu Y; Hawkins OE; Vilgelm AE; Pawlikowski JS; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
    Clin Cancer Res; 2015 Dec; 21(23):5338-48. PubMed ID: 26152738
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.
    Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B
    Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo.
    Sak M; Williams BJ; Zumbar CT; Teer L; Al-Kawaaz MNG; Kakar A; Hey AJ; Wilson MJ; Schier LM; Chen J; Lehman NL
    Cancer Chemother Pharmacol; 2023 Feb; 91(2):191-201. PubMed ID: 36694044
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
    Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
    Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of alisertib in treatment of peripheral T-cell lymphomas.
    Gallop-Evans E
    Future Oncol; 2015 Sep; 11(18):2515-24. PubMed ID: 26344156
    [TBL] [Abstract][Full Text] [Related]  

  • 53. VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells.
    Ding XF; Zhou J; Chen G; Wu YL
    Mol Med Rep; 2018 Jul; 18(1):1206-1210. PubMed ID: 29845253
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
    Zullo KM; Guo Y; Cooke L; Jirau-Serrano X; Mangone M; Scotto L; Amengual JE; Mao Y; Nandakumar R; Cremers S; Duong J; Mahadevan D; O'Connor OA
    Clin Cancer Res; 2015 Sep; 21(18):4097-109. PubMed ID: 25878331
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia.
    Katsha A; Soutto M; Sehdev V; Peng D; Washington MK; Piazuelo MB; Tantawy MN; Manning HC; Lu P; Shyr Y; Ecsedy J; Belkhiri A; El-Rifai W
    Gastroenterology; 2013 Dec; 145(6):1312-22.e1-8. PubMed ID: 23993973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alisertib Induces Cell Cycle Arrest, Apoptosis, Autophagy and Suppresses EMT in HT29 and Caco-2 Cells.
    Ren BJ; Zhou ZW; Zhu DJ; Ju YL; Wu JH; Ouyang MZ; Chen XW; Zhou SF
    Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26729093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRCA1 orchestrates the response to BI-2536 and its combination with alisertib in MYC-driven small cell lung cancer.
    Zhang J; Liu X; Hou P; Lv Y; Li G; Cao G; Wang H; Lin W
    Cell Death Dis; 2024 Jul; 15(7):551. PubMed ID: 39085197
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence.
    Liu Y; Hawkins OE; Su Y; Vilgelm AE; Sobolik T; Thu YM; Kantrow S; Splittgerber RC; Short S; Amiri KI; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
    EMBO Mol Med; 2013 Jan; 5(1):149-66. PubMed ID: 23180582
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
    Holt SV; Logié A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
    Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
    Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
    Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.